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Edited by Gianni CesareniAbstract Cochlin is colocalized with type II collagen in the
extracellular matrix of cochlea and has been suggested to inter-
act with this collagen. Here we show that the second von Wille-
brand type A domain of cochlin has aﬃnity for type II collagen,
as well as type I and type IV collagens whereas the LCCL-do-
main of cochlin has no aﬃnity for these proteins. The implica-
tions of these ﬁndings for the mechanism whereby cochlin
mutations cause the dominant negative DFNA9-type hearing loss
are discussed.
Structured summary:
MINT-6796048:
type I collagen (uniprotkb:P02452) binds (MI:0407) to cochlin-
vWA2 uniprotkb:O43405) by surface plasmon resonance
(MI:0107)
MINT-6796166:
type III collagen (uniprotkb:P02462) binds (MI:0407) to coch-
lin-vWA2 (uniprotkb:O43405) by surface plasmon resonance
(MI:0107)
MINT-6796062:
type II collagen (uniprotkb:P02458) binds (MI:0407) to cochlin-
vWA2 (uniprotkb:O43405) by surface plasmon resonance
(MI:0107)
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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domain1. Introduction
Cochlin is a major protein component of the extracellular
matrix of the inner ear; it is expressed by ﬁbrocytes in the spiral
limbus, spiral ligaments and the basilar membrane of the co-
chlea and throughout the vestibular end organs [1–4].
Cochlin consists of three domains: an amino-terminal
LCCL-domain and two von Willebrand type A domains
[1,5]. Mutations aﬀecting COCH, the gene encoding cochlin,
are known to be responsible for the autosomal dominant hu-
man deafness disorder DFNA9, a non-syndromic sensorineu-
ral progressive hearing loss associated with vestibular
dysfunction [5]. In the last decade, molecular analyses of cases
of DFNA9 have identiﬁed several families with diﬀerent
mutations in the human COCH gene. The majority of these*Corresponding author. Fax: +36 1 4665 465.
E-mail address: patthy@enzim.hu (L. Patthy).
0014-5793/$34.00  2008 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2008.10.050mutations were found in the region encoding the LCCL-do-
main, but recent studies have identiﬁed three diﬀerent muta-
tions that aﬀect the C-terminal von Willebrand type A
domain (for an up to date list of DFNA9 mutations see [6]
and references therein).
Despite a decade of intense research, relatively little is
known about the molecular function of cochlin or the mecha-
nism(s) whereby mutations of cochlin lead to slow progressive
hearing loss. The fact that auditory brainstem responses to
click and pure-tone stimuli were indistinguishable among
wild-type and homozygous Coch (/) mice expressing no
detectable cochlin indicates that DFNA9 is not caused by
COCH haploinsuﬃciency, but via a dominant negative or
gain-of-function eﬀect [7].
One generally accepted explanation for the dominant neg-
ative phenotype is that the mutations may cause misfolding
and precipitation of the mutant proteins. According to this
explanation the slow, progressive accumulation of cochlin
deposits in vestibular and cochlear nerve channels leads to
strangulation and progressive degeneration of the dendrites,
loss of cochlear and vestibular neurons and this results in
progressive hearing impairment and vestibular dysfunction.
The validity of this explanation is supported by several
observations. First, it has been shown that most of the muta-
tions that cause DFNA9-type deafness disorder aﬀect con-
served, structurally important residues of the LCCL-
domain; the mutations disrupt the normal structure of the
LCCL-fold and lead to protein misfolding [8]. Second, histo-
pathological studies detected insoluble acidophilic deposits in
temporal bone sections of individuals aﬀected by DFNA9 [9].
Furthermore, immunohistochemistry of temporal bone sec-
tions of a patient with a P51S mutation has revealed the pres-
ence of cochlin in the characteristic eosinophilic acellular
deposits in mesodermal structures of cochlea and vestibulum
[10].
A similar explanation may also hold for mutations aﬀecting
the C-terminal von Willebrand type A domain. Two novel
DFNA9 mutations in the vWA2 domain of cochlin, C542F
and C542Y, were found to change a cysteine residue that
forms an intrachain C362–C542 disulﬁde bond. Disruption
of this disulﬁde bond in the mutant cochlins may destabilize
the vWA2 domain and would also leave an unpaired cysteine
at position 362. This may lead to the formation of intermolec-
ular disulﬁde bonds between cochlin molecules or between
cochlin and other extracellular matrix proteins. It seems thus
possible that it is the accumulation of the mutant cochlins that
causes progressive hearing loss in patients aﬀected by these
mutations.blished by Elsevier B.V. All rights reserved.
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folding and deposition mechanism may not explain the ob-
served phenotype. For example, the W117R mutation aﬀects
a non-conserved, structurally not critical residue of the
LCCL-domain, the domain carrying the W117R mutation is
correctly folded and is as stable as the wild-type protein [8].
Similarly, the M512T mutation of the vWA2 domain of coch-
lin aﬀects a residue that is not highly conserved in vWA do-
mains therefore the mutation does not necessarily cause
severe misfolding of the mutant protein.
A possible explanation for the dominant negative patho-
genic eﬀect of mutant cochlins with correctly folded, stable
structures is that they may incorporate abnormally in the
extracellular matrix of the inner ear if the mutation aﬀects
interaction with other constituents of the extracellular matrix.
Grabski et al. [11] have indeed shown that mutations of coch-
lin that result in non-syndromic autosomal dominant deafness
(including the W117R mutation) change matrix deposition of
cochlin. Their data suggest that mutant cochlins fail to inte-
grate correctly into the extracellular matrix of the cochlear
and vestibular systems, leading to structural changes that are
likely to have pronounced eﬀects on the sensory function.
Nothing is known, however, about the extracellular matrix
constituent(s) that interact with cochlin but there are hints
for possible candidates. For example, the observation that
temporal bone sections of DFNA9 individuals lack the highly
structured bundles of type II collagen characteristic of healthy
individuals has led to the proposal that cochlin might interact
with type II collagen [9]. Recently, immunoelectronmicroscop-
ic analysis of rat semicircular canal detected immunolabelling
for cochlin and for type II collagen in the same ﬁbrillar sub-
stance in the subepithelial area [12].
The colocalization of cochlin and type II collagen in inner
ear structures has prompted us to investigate the interaction
of this collagen with diﬀerent domains of cochlin. In this work
we show that the second von Willebrand factor type A domain
of cochlin has high aﬃnity for type II collagen, as well as type I
and type IV collagens, but its LCCL-domain displayed no
detectable aﬃnity for these proteins.2. Materials and methods
2.1. Proteins and reagents
Acid-soluble human collagen types I, II and IV were purchased from
Chemicon International. CM5 sensorchips and the reagents for protein
coupling to the chips were from Biacore AB. Recombinant LCCL-do-
main of human cochlin was produced in Escherichia coli as described
previously [13].2.2. Cloning and expression of the von Willebrand factor type A domains
of human cochlin in Pichia pastoris
The second von Willebrand factor type A domain of human cochlin
(coch_vWA2) was expressed in the methylotrophic yeast, P. pastoris,
utilizing the pPICZaA expression vector of Easy Select P. pastoris
expression kit. The DNA segment encoding coch_vWA2 was ampliﬁed
with the 5GCGAGAATTCAGCAAGACCTGTTATAACTCA3
sense and 5GCGGCATGCCTCGAGTTGCTGGGATTCTAA-
GAAATC 3 antisense primers from a human pancreas cDNA library.
P. pastoris GS115 (his 4) strain was transformed with the pPICZaA-
vWA2 vector by electroporation, and positive transformants were se-
lected on Zeocin containing YPDS plates (1% yeast extract, 2% pep-
tone, 2% dextrose, 1M sorbitol, 100 lg/ml zeocin) as described in thePichia Expression System users manual of Invitrogen. Genomic
DNA was prepared from Zeocin resistant colonies to verify the inte-
gration of the expression plasmid into the yeast chromosome.
P. pastoris clones harboring the expression plasmid were grown in
400 ml medium containing 2% peptone, 1% yeast extract and 5% glyc-
erol for 72 h then the medium was changed to induction medium con-
taining 100 mM potassium phosphate, pH 7.5, 0.2% ammonium
sulphate, 0.34% yeast nitrogen base, 0.004% histidine, 0.00004% biotin
and 1% methanol and were shaken for 48 h. Methanol addition was re-
peated at every 24 h.
The cells were centrifuged and the supernatant was applied onto Ni-
aﬃnity column. Unbound components were removed by washing with
10 column volumes of 20 mM Tris, 500 mM NaCl, 30 mM imidazole
buﬀer, pH 7.9. The bound recombinant protein was eluted with
20 mM Tris, 300 mM imidazole buﬀer, pH 7.9. The eluted protein
was lyophilized, then dissolved in 0.1 M ammonium bicarbonate buf-
fer, pH 8.0, and desalted on a Sephadex G-25 column equilibrated with
0.1 M ammonium bicarbonate buﬀer, pH 8.0. The protein was further
puriﬁed on a Sephacryl S-300 column equilibrated with 0.1 M ammo-
nium bicarbonate, pH 8.0, buﬀer. Fractions containing the pure
coch_vWA2 protein were pooled and lyophilized.
The DNA segment encoding the ﬁrst vWA domain of human coch-
lin (coch_vWA1) was ampliﬁed with the 5GCGAGAATTCACTGG-
CAATAAAGATTGTAAA3 sense and 5GCGACTCGAGCAG
AGGCTTTACGTATTTTGT 3 antisense primers. The ampliﬁed
DNA was digested with EcoRI and XhoI restriction enzymes and li-
gated into pPICZaA vector cut with EcoRI and SalI enzymes.
Although integration of the expression plasmid into the yeast chromo-
some was veriﬁed by PCR, none of theP. pastoris clones harboring the
expression plasmid produced detectable amount of the recombinant
protein containing coch_vWA1.
2.3. Protein analyses
The concentrations of the recombinant proteins were determined
using the following extinction coeﬃcients: coch_LCCL,
10 930 M1 cm1; coch_vWA2, 13 075 M1 cm1. The extinction coef-
ﬁcient was determined with the online protein analysis tool, ProtParam
(http://us.expasy.org/tools/protparam.html). N-terminal sequencing
was performed on an Applied Biosystems 471A protein sequencer with
an online ABI 120A phenyltiohydantoin (PTH) analyser.
2.4. Circular dichroism spectroscopy
CD spectra of coch_vWA2 were measured over the range of 195–
250 nm with a JASCO J-720 spectropolarimeter thermostated with a
Neslab RTE-11 1 water bath. The measurements were carried out in
1 mm pathlength cells using protein solutions of 0.2 mg/ml in 25 mM
Tris–HCl, pH 8.0. Spectra were measured at 25 C with a 8 s time con-
stant and a scan rate of 20 nm/min. The spectral slit width was 1.0 nm.
Secondary structure of the recombinant protein was estimated from
the CD spectra with the CDPro software (http://lamar.Colo-
state.EDU/~sreeram/CDPro/index.html)
The spectra of the recombinant protein were also recorded at diﬀer-
ent temperatures from 25 C to 85 C at 10 C intervals. The thermal
unfolding of the protein was monitored at 222 nm, where the diﬀerence
of the CD spectra recorded at diﬀerent temperatures was the largest.
The heating rate was 50 C/h. Melting temperature was determined
by derivative processing of changes in CD at 222 nm using the spectra
analysis program for WINDOWS 95/NT version 1.53.04 (JASCO).
2.5. Surface plasmon resonance analysis
Surface plasmon resonance measurements were performed on a
BIAcore X instrument. For immobilization, acid-soluble human colla-
gens type I, II and IV were dissolved in 50 mM sodium acetate, pH 4.5,
at a ﬁnal concentration of 30 lg/ml, and 50 ll of these solutions were
injected with 5 ll/min ﬂow rate for 10 min on a CM5 sensorchip acti-
vated by the amine coupling method according to the instructions of
the manufacturer.
For interaction measurements, 80 ll samples containing diﬀerent
concentrations of coch_vWA2 or coch_LCCL as analyte were injected
at a ﬂow rate of 20 ll/min, followed by wash with buﬀer at a ﬂow rate
of 20 ll/min. Binding and washes were performed in 20 mM HEPES,
150 mM NaCl, 1 mM EDTA, 0.005% Tween 20 buﬀer, pH 7.5. After
each cycle the chips were regenerated with a 5 ll pulse of 25 mM
NaOH at a ﬂow rate of 20 ll/min.
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in the presence of coupling buﬀer alone. Control sensorgrams were
subtracted from sensorgrams obtained with immobilized ligand. To
correct for diﬀerences between the reaction and reference surfaces,
we have also subtracted the average of sensorgrams obtained with
blank running buﬀer injections.
The kinetic parameters for each interaction were determined by ﬁt-
ting the experimental data with BIAevaluation software 4.0, and the
closeness of the ﬁts was characterized by the v2 values. Only ﬁts with
v2 values lower than 5% of the Rmax were accepted. The data were ﬁt-
ted to a model of 1:1 Langmuir interaction.
To study the eﬀect of diﬀerent cations on the binding properties of
coch_vWA2 to collagens, the protein was diluted in Tris-buﬀered sal-
ine buﬀer containing 1 mM of either Ca2+ or Mg2+ or 100 lM of Zn2+
and was injected over the chip. In these experiments the running buﬀer
was 20 mM Tris–HCl, 150 mM NaCl, 0.005% Tween 20, pH 7.5 sup-
plemented with the appropriate cation.3. Results
3.1. Expression and characterization of the second von
Willebrand factor type A domain of cochlin
Analysis of the culture media of Pichia transformed with
pPICZaA-vWA2 revealed that a protein of approximately
22 kDa molecular mass is secreted. The N-terminal amino acid
sequence of the secreted protein was found to beFig. 1. Characterization of the recombinant vWA2 domain of human
cochlin by circular dichroism spectroscopy. (A) Far-ultraviolet circular
dichroism spectra of recombinant vWA2 domain. The solid line
indicates the spectrum of the recombinant protein, the dashed line
indicates the CDPro-predicted spectrum of a protein consisting of
16.5% regular beta strand, 9.2% distorted beta strand, 12.5% regular
helix and 11.4% distorted helix, 21.2% turn and 29.2% unordered
structure. (B) Determination of the melting temperature of recombi-
nant vWA2 domain based on temperature dependence of its CD
spectra. Changes in the CD of the protein were monitored at 222 nm.EAEAEFSKTCYNS; residues of the second vWA domain of
cochlin are highlighted in bold, the residues in italic originate
from the vector. The calculated molecular mass of recombi-
nant coch_vWA was 22.762 Da; the agreement of the predictedFig. 2. Characterization of the interaction of the vWA2 domain of
human cochlin with type I, type II and type IV human collagens by
surface plasmon resonance assays. Sensorgrams of the interactions of
(A) vWA2 domain (0.2 lM, 0.25 lM, 0.5 lM, 1 lM and 2 lM) with
type I human collagen; (B) vWA2 domain (0.25 lM, 0.5 lM, 1 lM and
2 lM) with type II human collagen; (C) vWA2 domain (0.3 lM,
0.5 lM, 1 lM, 1.5 lM, and 2 lM) with type IV human collagen.
Table 1
Kinetic parameters of the interaction of the vWA2 domain of human
cochlin with human type I, type II and type IV collagens. The rate
constants of the association and dissociation reactions and the
equilibrium dissociation constants of the interactions were determined
from surface plasmon resonance measurements with the Biaevaluation
software 4.0.
Interacting proteins Kd value ka kd
Collagen type I* – vWA2 7.97 · 108 1.14 · 103 9.07 · 105
Collagen type II* – vWA2 9.45 · 108 2.10 · 103 1.98 · 104
Collagen type IV* – vWA2 1.10 · 107 4.14 · 103 4.57 · 104
*Proteins marked by an asterisk were immobilized on sensorchips.
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protein is not glycosylated.
The structural integrity of the vWA domain of recombinant
coch_vWA2 was analyzed by CD spectroscopy. The circular
dichroism spectrum of coch_vWA2 domain (Fig. 1A). is very
similar to those of other members of the vWA-domain family
[14,15] inasmuch as it is also characterized by a large negative
ellipticity between 210 and 225 nm and a small trough between
these wavelengths.
Analysis of the CD spectra of coch_vWA2 with the CDPro
software indicates that the protein-fold contains 16.5% regular
beta strand, 9.2% distorted beta strand, 12.5% regular helix
and 11.4% distorted helix, 21.2% turn and 29.2% unordered
structure, consistent with the fact that vWA-domains consist
of a b sheet wrapped by multiple a helices [16,17].
The thermal unfolding of coch_vWA2 has been character-
ized by monitoring changes of its CD spectra. As shown in
Fig. 1B, changes in the CD spectra at 220 nm reﬂect a single,
sharp transition with a Tm value of 52 C, indicating a native
fold that collapses in a highly cooperative fashion.
3.2. Type I, type II and type IV collagens bind the vWA2 domain
but not the LCCL-domain of cochlin
Recombinant coch_vWA2 was found to bind to collagens
type I, type II and type IV immobilized on the surface of the
sensor chips (Fig. 2A–C). Evaluation of the sensorgrams re-
vealed that the equilibrium dissociation constants for the inter-
action of coch_vWA2 with type I, type II and type IV
collagens were 7.97 · 108 M, 9.45 · 108 M and
1.10 · 107 M, respectively (Table 1). SPR measurements were
also performed in the presence of 1 mM Ca2+, 1 mM Mg2+ or
100 lM Zn2+. Addition of these metal ions had no detectable
eﬀect on the aﬃnity of coch_vWA2 to these collagens (data
not shown).
On the other hand, when solutions of coch_LCCL were in-
jected onto the sensorchips containing immobilized type I, type
II and type IV collagens no interaction was detected even with
the highest concentrations (5 lM) of coch_LCCL tested (data
not shown).4. Discussion
Our observation that the C-terminal von Willebrand type A
domain of cochlin has aﬃnity for type II collagen conﬁrms
earlier suggestions that cochlin might interact with this colla-
gen and that such an interaction might play a crucial role in
the structural homeostasis of the vestibule [9,12].The involvement of a von Willebrand type A domain of
cochlin in collagen binding is not unexpected in view of the
fact that in many cases vWA domains of extracellular matrix
constituents, cell surface receptors act as adhesion sites for col-
lagens [18,19].
vWA domains are Rossmann folds consisting of a b sheet
wrapped by multiple a helices [16,17]. Many vWA domains
bind divalent metal ions via a noncontiguous sequence motif
called Metal Ion Dependent Adhesion Site (MIDAS). MIDAS
is made up of ﬁve conserved metal ion-coordinating residues
three of which constitute the linear motif Asp-Xaa-Ser-Xaa-
Ser; the remaining two MIDAS residues (a Thr and an Asp
residue) are located in more distant downstream sequence re-
gions of vWA domains (e.g. [20]. In the case of integrins the
cation complexed with the MIDAS motif of the vWA-domain
is involved in ligand binding [20]. It is noteworthy, however,
that the vWA3 domain of von Willebrand factor, which serves
as the principal binding site of this protein for collagens type I
and type III, does not contain a metal ion-dependent adhesion
site motif and collagen recognition by this vWA domain occurs
by a mechanism diﬀerent from that of integrins [21]. Structural
studies on the vWA3 domain of von Willebrand factor have in-
deed revealed that the collagen-binding site is located distant
from the face of the domain where collagen-binding sites are
found in homologous vWA domain of integrins [22,23].
The MIDAS motif is also conserved in vWA2 of cochlins:
residues Asp-373, Ser-375, Ser-377, Thr-446 and Asp-475 of
human cochlin may provide a binding site for divalent cations.
Nevertheless, our observation that the aﬃnity of cochlins
vWA2 domain for type I, type II and type IV collagens is
not inﬂuenced by the presence of EDTA or the addition of
Ca2+, Mg2+ or Zn2+ suggests that collagen recognition by this
vWA domain occurs by a mechanism diﬀerent from that of
integrins.
Since we do not yet know the three-dimensional structure of
the vWA2 domain of cochlin and the location of the collagen-
binding site on this domain, it is hard to assess the impact of
the M512T mutation on the vWA-fold or the collagen-binding
site. Nevertheless, the present ﬁndings raise the possibility that
mutations eliminating cochlins interaction with other constit-
uents of the extracellular matrix of the inner ear may interfere
with the normal cochlear function. In this work we provide
experimental evidence that the vWA2 domain of cochlin does
interact with type I, type II and type IV collagens, but the iden-
tity of matrix constituent(s) that might interact with its LCCL-
domain remains unknown.
Acknowledgement: This work was supported by Grant 49890 of the
National Scientiﬁc Research Fund of Hungary (OTKA) of Hungary.References
[1] Robertson, N.G., Skvorak, A.B., Yin, Y., Weremowicz, S.,
Johnson, K.R., Kovatch, K.A., et al. (1997) Mapping and
characterization of a novel cochlear gene in human and in mouse:
a positional candidate gene for a deafness disorder, DFNA9.
Genomics 46, 345–354.
[2] Ikezono, T., Omori, A., Ichinose, S., Pawankar, R., Watanabe, A.
and Yagi, T. (2001) Identiﬁcation of the protein product of the
Coch gene (hereditary deafness gene) as the major component of
bovine inner ear protein. Biochim. Biophys. Acta 1535, 258–265.
[3] Robertson, N.G., Resendes, B.L., Lin, J.S., Lee, C., Aster, J.C.,
Adams, J.C., et al. (2001) Inner ear localization of mRNA and
I. Nagy et al. / FEBS Letters 582 (2008) 4003–4007 4007protein products of COCH, mutated in the sensorineural deafness
and vestibular disorder, DFNA9. Hum. Mol. Genet. 10, 2493–
2500.
[4] Kommareddi, P.K., Nair, T.S., Raphael, Y., Telian, S.A., Kim,
A.H., Arts, H.A., et al. (2007) Cochlin isoforms and their
interaction with CTL2 (SLC44A2) in the inner ear. J. Assoc.
Res. Otolaryngol. 8, 435–446.
[5] Robertson, N.G., Lu, L., Heller, S., Merchant, S.N., Eavey, R.D.,
McKenna, M., et al. (1998) Mutations in a novel cochlear gene
cause DFNA9, a human nonsyndromic deafness with vestibular
dysfunction. Nat. Genet. 20, 299–303.
[6] Robertson, N.G., Jones, S.M., Sivakumaran, T.A., Giersch, A.B.,
Jurado, S.A., Call, L.M., Miller, C.E., Maison, S.F., Liberman,
M.C. and Morton, C.C. (2008) A targeted Coch missense
mutation: a knock-in mouse model for DFNA9 late-onset hearing
loss and vestibular dysfunction. Hum. Mol. Genet. 17, 3426–3434.
[7] Makishima, T., Rodriguez, C.I., Robertson, N.G., Morton, C.C.,
Stewart, C.L. and Griﬃth, A.J. (2005) Targeted disruption of
mouse Coch provides functional evidence that DFNA9 hearing
loss is not a COCH haploinsuﬃciency disorder. Hum. Genet. 118,
29–34.
[8] Liepinsh, E., Trexler, M., Kaikkonen, A., Weigelt, J., Ba´nyai, L.,
Patthy, L., et al. (2001) NMR structure of the LCCL domain and
implications for DFNA9 deafness disorder. EMBO J. 20, 5347–
5353.
[9] Khetarpal, U. (2000) DFNA9 is a progressive audiovestibular
dysfunction with a microﬁbrillar deposit in the inner ear.
Laryngoscope 110, 1379–1384.
[10] Robertson, N.G., Cremers, C.W., Huygen, P.L., Ikezono, T.,
Krastins, B., Kremer, H., et al. (2006) Cochlin immunostaining
of inner ear pathologic deposits and proteomic analysis in
DFNA9 deafness and vestibular dysfunction. Hum. Mol. Genet.
15, 1071–1085.
[11] Grabski, R., Szul, T., Sasaki, T., Timpl, R., Mayne, R., Hicks, B.,
et al. (2003) Mutations in COCH that result in non-syndromic
autosomal dominant deafness (DFNA9) aﬀect matrix deposition
of cochlin. Hum. Genet. 113, 406–416.
[12] Mizuta, K., Ikezono, T., Iwasaki, S., Arai, M., Hashimoto, Y.,
Pawankar, R., et al. (2008) Ultrastructural co-localization of
cochlin and type II collagen in the rat semicircular canal.
Neurosci. Lett. 434, 104–107.
[13] Trexler, M., Ba´nyai, L. and Patthy, L. (2000) The LCCL module.
Eur. J. Biochem. 267, 5751–5757.[14] Fairbanks, M.B., Pollock, J.R., Prairie, M.D., Scahill, T.A.,
Baczynskyj, L., Heinrikson, R.L., et al. (1995) Puriﬁcation and
structural characterization of the CD11b/CD18 integrin alpha
subunit I domain reveals a folded conformation in solution. FEBS
Lett. 369, 197–201.
[15] Hinshelwood, J. and Perkins, S.J. (2000) Metal-dependent con-
formational changes in a recombinant vWF-A domain from
human factor B: a solution study by circular dichroism, fourier
transform infrared and (1)H NMR spectroscopy. J. Mol. Biol.
298, 135–147.
[16] Huizinga, E.G., Martijn van der Plas, R., Kroon, J., Sixma, J.J.
and Gros, P. (1997) Crystal structure of the A3 domain of human
von Willebrand factor: implications for collagen binding. Struc-
ture 5, 1147–1156.
[17] Emsley, J., Cruz, M., Handin, R. and Liddington, R. (1998)
Crystal structure of the von Willebrand Factor A1 domain and
implications for the binding of platelet glycoprotein Ib. J. Biol.
Chem. 273, 10396–10401.
[18] Tuckwell, D.S., Reid, K.B., Barnes, M.J. and Humphries, M.J.
(1996) The A-domain of integrin alpha 2 binds speciﬁcally to a
range of collagens but is not a general receptor for the collagenous
motif. Eur. J. Biochem. 241, 732–739.
[19] Hoylaerts, M.F., Yamamoto, H., Nuyts, K., Vreys, I., Deckmyn,
H. and Vermylen, J. (1997) Von Willebrand factor binds to native
collagen VI primarily via its A1 domain. Biochem. J. 324, 185–
191.
[20] Xiong, J.P., Stehle, T., Zhang, R., Joachimiak, A., Frech, M.,
Goodman, S.L., et al. (2002) Crystal structure of the extracellular
segment of integrin alpha Vbeta3 in complex with an Arg-Gly-
Asp ligand. Science 296, 151–155.
[21] Bienkowska, J., Cruz, M., Atiemo, A., Handin, R. and Lidding-
ton, R. (1997) The von willebrand factor A3 domain does not
contain a metal ion-dependent adhesion site motif. J. Biol. Chem.
272, 25162–25167.
[22] Romijn, R.A., Bouma, B., Wuyster, W., Gros, P., Kroon, J.,
Sixma, J.J., et al. (2001) Identiﬁcation of the collagen-binding site
of the von Willebrand factor A3-domain. J. Biol. Chem. 276,
9985–9991.
[23] Romijn, R.A., Westein, E., Bouma, B., Schiphorst, M.E., Sixma,
J.J., Lenting, P.J., et al. (2003) Mapping the collagen-binding site
in the von Willebrand factor-A3 domain. J. Biol. Chem. 278,
15035–15039.
